In a filing, Arcutis Biotherapeutics Inc revealed its Director Heron Patrick J acquired Company’s shares for reported $0.2 million on Mar 04 ’24. In the deal valued at $9.50 per share,21,052 shares were bought. As a result of this transaction, Heron Patrick J now holds 8,785,284 shares worth roughly $89.61 million.
Then, Watanabe Todd Franklin sold 14,903 shares, generating $165,739 in total proceeds. Upon selling the shares at $11.12, the insider now owns 874,533 shares.
Before that, Burnett Patrick sold 4,782 shares. Arcutis Biotherapeutics Inc shares valued at $53,182 were divested by the insider at a price of $11.12 per share. As a result of the transaction, Burnett Patrick now holds 269,300 shares, worth roughly $2.75 million.
Mizuho upgraded its Arcutis Biotherapeutics Inc [ARQT] rating to a Buy from a a Neutral in a research note published on January 03, 2024; the price target was increased to $8 from $4. A number of analysts have revised their coverage, including Mizuho’s analysts, who decreased its forecast for the stock in late October from “a Buy” to “a Neutral”. Goldman also remained covering ARQT and has decreased its forecast on October 13, 2023 with a “Neutral” recommendation from previously “Buy” rating. Needham started covering the stock on September 07, 2022. It rated ARQT as “a Buy”.
Price Performance Review of ARQT
On Friday, Arcutis Biotherapeutics Inc [NASDAQ:ARQT] saw its stock fall -14.14% to $10.20. Over the last five days, the stock has lost -10.05%. Arcutis Biotherapeutics Inc shares have risen nearly 215.79% since the year began. Nevertheless, the stocks have fallen -23.08% over the past one year. While a 52-week high of $15.40 was reached on 04/09/24, a 52-week low of $1.76 was recorded on 01/02/24. SMA at 50 days reached $9.55, while 200 days put it at $6.49. A total of 4.16 million shares were traded, compared to the trading of 2.74 million shares in the previous session.
Levels Of Support And Resistance For ARQT Stock
The 24-hour chart illustrates a support level at 9.42, which if violated will result in even more drops to 8.64. On the upside, there is a resistance level at 11.38. A further resistance level may holdings at 12.56. The Relative Strength Index (RSI) on the 14-day chart is 48.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.88, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.79%. Stochastics %K at 58.42% indicates the stock is a holding.
The most recent change occurred on March 17, 2022 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $45 price target.
